Letter comments on: "Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'". [PDF]
ESMO Open, 2022 Müller B, Estay R.
europepmc +1 more source
Australia makes concessions on drug approvals after US pressure [PDF]
, 2004 Bob Burton
openalex +1 more source
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials. [PDF]
Blood Adv, 2022 Kanapuru B +11 more
europepmc +1 more source
Benefits and Costs of Newer Drugs: An Update [PDF]
We update and extend our previous study of the effect of drug age -- years since FDA approval -- on total medical expenditure, in several respects. The estimates indicate that, in the entire population, a reduction in the age of drugs utilized reduces ...
Frank Lichtenberg
core
The Two Towers: Quest for Drugs from Discovery to Approval [PDF]
, 2004 Ron Cohen, Patrick J. Potter
openalex +1 more source
Assessment of the impact of Japanese-specific long-term safety data on new drug approval. [PDF]
Clin Transl Sci, 2021 Uzu S, Sekine S, Asano J, Ikuma M.
europepmc +1 more source
Drug approval system questioned in US and Canada [PDF]
, 2005 Laura Eggertson
openalex +1 more source
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process [PDF]
, 2005 Ernst R. Berndt +3 more
openalex +1 more source
Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'. [PDF]
ESMO Open, 2021 Grössmann N +3 more
europepmc +1 more source